Up­dat­ed: Astel­las low­ers sales ex­pec­ta­tions for menopause drug, aims to ‘re­pro­duce’ hype for Veozah with an­oth­er Su­per Bowl ad

Astel­las, which is ready­ing a Su­per Bowl ad for its hot flash menopause treat­ment Veozah, sig­nif­i­cant­ly cut the drug’s sales fore­cast for the year, cit­ing slug­gish com­mer­cial up­take.

The Japan­ese drug­mak­er said Mon­day it now ex­pects 7.1 bil­lion yen ($50 mil­lion) in sales of Veozah in fis­cal 2023, down from 53 bil­lion yen ($375 mil­lion). The drug, which was ap­proved by the FDA in May, brought in 3.6 bil­lion yen ($25 mil­lion) through the third quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER